title: Oxaliplatin, fluorouracil and leucovorin for advanced biliary system adenocarcinomas: a prospective phase II trial.
abstract: We studied the activity of combined oxaliplatin and fluorouracil-leucovorin in 16 consecutive patients with advanced biliary tract adenocarcinomas. The disease control rate (responses and stable disease) was 56% (95% confidence interval, 29-84%) and the median overall survival time was 9.5 months (range 0.9-26.8+). Therefore, this regimen might be active in biliary adenocarcinomas with further evaluation necessary.
authors.affiliation: Department of Internal Medicine I, University Hospital, Otfried-Müller-Str. 10, 72076 Tübingen, Germany. oliver.nehls@uni-tuebingen.de
authors.forename: O
authors.initials: O
authors.lastname: Nehls
authors.forename: B
authors.initials: B
authors.lastname: Klump
authors.forename: H T
authors.initials: HT
authors.lastname: Arkenau
authors.forename: H G
authors.initials: HG
authors.lastname: Hass
authors.forename: A
authors.initials: A
authors.lastname: Greschniok
authors.forename: M
authors.initials: M
authors.lastname: Gregor
authors.forename: R
authors.initials: R
authors.lastname: Porschen
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000473:pathology; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001661:Biliary Tract Neoplasms / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use*; D006801:Humans; D002955:Leucovorin / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009944:Organoplatinum Compounds / Q000627:therapeutic use*; D000077150:Oxaliplatin; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D002955:Leucovorin; D005472:Fluorouracil